WO2018167536A1 - Matériau implantable et procédé de conservation - Google Patents

Matériau implantable et procédé de conservation Download PDF

Info

Publication number
WO2018167536A1
WO2018167536A1 PCT/IB2017/051504 IB2017051504W WO2018167536A1 WO 2018167536 A1 WO2018167536 A1 WO 2018167536A1 IB 2017051504 W IB2017051504 W IB 2017051504W WO 2018167536 A1 WO2018167536 A1 WO 2018167536A1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
glycerol
solution
vol
polyols
Prior art date
Application number
PCT/IB2017/051504
Other languages
English (en)
Inventor
Marina Strasly
Original Assignee
Sorin Group Italia S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorin Group Italia S.R.L. filed Critical Sorin Group Italia S.R.L.
Priority to PCT/IB2017/051504 priority Critical patent/WO2018167536A1/fr
Publication of WO2018167536A1 publication Critical patent/WO2018167536A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/505—Stabilizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633—Extracellular matrix [ECM]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking

Definitions

  • the present invention relates to implantable materials. More specifically, the invention relates to decellularized implantable materials or tissue engineered implantable materials and methods for producing and preserving such implantable materials.
  • Biological prostheses are medical devices that use mammalian donor tissues.
  • suitable mammalian tissues include, for example, bovine, porcine, ovine, equine, and human tissues.
  • the donor tissue may include, for example, cardiac valves, pericardium, tendons, ligaments, dura mater, skin, and veins.
  • tissues used in biological prostheses undergo a series of chemical treatments in order to give biological and mechanical stability to the tissue itself and to sterilize the final device that incorporates the tissue.
  • These chemical treatments typically involve aldehydes able to crosslink the tissue to alter its mechanical properties, reduce in vivo enzymatic digestion and immune response after implant and, in combination with other chemicals, to sterilize the device.
  • Aldehyde treatments result in a stable device that is resistant to remodeling or degradation by the patient's body after implant. This stability in general is seen as an advantage, but for certain advanced applications it represents a drawback.
  • a biological heart valve implanted within a child able to be remodeled and grow with the child may reduce the need to replace the heart valve as the child grows.
  • Recent technical development in tissue engineering and in native tissue decellularization are devoted to producing new tissues that are not fixed so that the recipient organism can remodel donor tissue in some way, by repopulating it with the recipient's own cells.
  • Example 1 is an implantable material including decellularized sterilized mammalian tissue having an extracellular matrix, wherein a plurality of interstitial spaces of the extracellular matrix include a solution of one or more polyols other than glycerol and, optionally, glycerol.
  • Example 2 the implantable material of Example 1 , wherein the glycerol is present in an amount of about 1 vol. % to about 50 vol. % of the mixture and the one or more polyols other than glycerol are present in an amount of about 50 vol. % to about 99 vol. % of the mixture.
  • Example 3 the implantable material of either of Examples 1 or 2, wherein the solution in the plurality of interstitial spaces of the extracellular matrix consists essentially of the one or more polyols other than glycerol and glycerol.
  • Example 4 the implantable material of any of Examples 1 -3, wherein the one or more polyols other than glycerol includes at least one of 1 ,2 propanediol, 1 ,2 octanediol, 1 ,4 butanediol, fructose, xylitol, mannitol, sorbitol, lactulose, lactic acid, maltose, glucose, galactose, erythritol, lactobionic acid or its salts, and hyaluronic acid.
  • the one or more polyols other than glycerol includes at least one of 1 ,2 propanediol, 1 ,2 octanediol, 1 ,4 butanediol, fructose, xylitol, mannitol, sorbitol, lactulose, lactic acid, maltose, glucose, galactose, eryth
  • Example 5 the implantable material of any of Examples 1 -4, wherein the one or more polyols other than glycerol are selected from the group consisting of 1 ,2 propanediol, 1 ,4 butanediol, lactobionic acid and its salts, and combinations thereof.
  • Example 6 the implantable material of any of Examples 1 -5, wherein the one or more polyols other than glycerol consists essentially 1 ,2 propanediol.
  • Example 7 the implantable material of any of Examples 1 -6, wherein the implantable material is substantially free of water.
  • Example 8 the implantable material of any of Examples 1 -6, wherein the implantable material is non-fixed.
  • Example 9 the implantable material of any of Examples 1 -8, wherein the implantable material forms a portion of an engineered heart valve.
  • Example 10 is method for making an implantable material.
  • the method includes decellularizing mammalian tissue, treating the decellularized mammalian tissue with a solution; drying the treated tissue, and sterilizing the dried tissue.
  • the treatment solution includes one or more polyols other than glycerol, glycerol and, optionally, water.
  • Example 1 1 the method of Example 10, wherein the solution includes the glycerol at a concentration from about 15 vol. % to about 35 vol. %, the one or more polyols other than glycerol at a concentration of about 65 vol. % to about 85 vol. % of the solution, and the balance water.
  • Example 12 the method of either of Examples 10 or 1 1 , wherein the solution consists essentially of the one or more polyols other than glycerol, glycerol, and, optionally, water.
  • Example 13 the method of any of Examples 10-12, wherein sterilizing includes at least one of exposing the dried tissue to ethylene oxide gas, exposing the dried tissue to ionizing radiation, and exposing the dried tissue to ultraviolet light.
  • Example 14 the method of any of Examples 10-13, wherein drying the treated tissue includes drying until substantially all water is removed from the treated tissue.
  • Example 15 the method of any of Examples 10-14, wherein treating the tissue includes immersing the tissue in the solution.
  • Example 16 the method of Example 15, wherein the tissue is immersed in the solution for a time ranging from 2 to 100 hours and at a temperature ranging from 5°C to 35°C.
  • Example 17 the method of either of Examples 15 or 16, wherein the tissue is immersed in the solution more than once.
  • Example 18 the method of Examples 10-14, wherein treating the tissue includes one of spraying the solution on the tissue and spreading the solution on the tissue.
  • Example 19 the method of any of Examples 10-18, wherein the one or more polyols other than glycerol includes at least one of 1 ,2 propanediol, 1 ,2 octanediol, 1 ,4 butanediol, fructose, xylitol, mannitol, sorbitol, lactulose, lactic acid, maltose, glucose, galactose, erythritol, lactobionic acid or its salts, and hyaluronic acid.
  • the one or more polyols other than glycerol includes at least one of 1 ,2 propanediol, 1 ,2 octanediol, 1 ,4 butanediol, fructose, xylitol, mannitol, sorbitol, lactulose, lactic acid, maltose, glucose, galactose, erythrito
  • Example 20 the method of any of Examples 10-19, wherein the one or more polyols other than glycerol are selected from the group consisting of 1 ,2 propanediol, 1 ,4 butanediol, lactobionic acid, and combinations thereof.
  • Example 21 the method of any of Examples 10-20, wherein solution includes the glycerol at a concentration from about 15 vol. % to about 35 vol. %, the one or more polyols other than glycerol at a concentration of about 65 vol. % to about 85 vol. % of the solution, and the balance ethanol.
  • Example 22 the method of any of Examples 10-21 , wherein the tissue is not treated with a fixing agent.
  • Example 23 is a preserved tissue engineered heart valve including decellularized, non-fixed, sterilized mammalian tissue having an extracellular matrix, wherein a plurality of interstitial spaces of the extracellular matrix includes a solution consisting essentially of one or more polyols other than glycerol and glycerol, wherein the glycerol is no more than 50 vol. % of the solution.
  • FIG. 1 is a photograph of a non-fixed decellularized tissue sample treated with pure glycerol.
  • FIG. 2 is a photograph of a non-fixed decellularized tissue sample treated with pure 1 ,2 propanediol, according to embodiments.
  • FIG. 3 is a photograph of a non-fixed decellularized tissue sample treated with a solution of 1 ,2 propanediol and glycerol, according to embodiments.
  • FIG. 4 is a photograph of a stented valve made of non-fixed decellularized pericardium and treated with a solution of 1 ,2 propanediol and glycerol, according to embodiments.
  • FIG. 5 is a photograph of a fixed tissue sample treated with pure glycerol.
  • FIG. 6 is a photograph of a fixed tissue sample treated with pure 1 ,2 propanediol, according to embodiments.
  • FIG. 7 is a photograph of a fixed tissue sample treated with a solution of 1 ,2 propanediol and glycerol, according to embodiments.
  • FIG. 8 is a photograph of a fixed tissue sample treated with a solution of 1 ,4 butanediol and glycerol, according to embodiments.
  • FIGS. 9A and 9B are photographs showing opposite sides of a heart valve made of fixed tissue treated with pure glycerol.
  • FIGS. 10A and 10B are photographs showing opposite sides of a heart valve made of fixed tissue treated with pure 1 ,2 propanediol, according to embodiments.
  • FIGS. 1 1A and 1 1 B are photographs showing opposite sides of a heart valve made of fixed tissue treated with a solution of 1 ,2 propanediol and glycerol, according to embodiments.
  • crosslinking or "fixing" of the extracellular matrix improves the strength and biological durability of the tissue.
  • Aldehyde based processes are a typical example of this approach. Aldehyde based processes are also used to provide chemical sterilization to the bioprosthesis. Applied to a decellularized tissue or to a material obtained via tissue engineering, these crosslinking/sterilization methods reduce the ability of the tissue to remodel. In some applications, crosslinking or "fixing" of the extracellular matrix improves the strength and biological durability of the tissue, but the use of the crosslinking agent usually destroys the potential for the patient's body to favorably remodel the tissue.
  • Remodeling refers to the action by the host body to replace some or all of the extracellular matrix of the implanted tissue, with new tissue produced by host cells of the patient's body repopulating the implanted tissue.
  • the extracellular matrix acts as a scaffold to guide the growth of the new tissue.
  • a tissue engineered heart valve implanted within a child may be remodeled and grow with the child, reducing the need to replace the heart valve as the child grows.
  • Fixed (i.e., crosslinked) tissue cannot be remodeled by the body because of the structural fixation and/or cytotoxicity imparted by crosslinking the collagen of the extracellular matrix of the donor tissue.
  • Embodiments of this disclosure include an implantable material including decellularized, non-fixed mammalian tissue that is sterilized and preserved sterile and dry without impairing the ability of the extracellular matrix to be remodeled.
  • Other embodiments include an implantable material including decellularized mammalian tissue that has been fixed. In either case, the decellularized tissue may be made by removing the cells from mammalian tissue, such as a porcine heart valve, leaving behind the extracellular matrix.
  • Other mammalian tissues may include bovine pericardium, equine pericardium or other porcine tissues such as the intestinal mucosa.
  • the tissue may be made by seeding a polymeric mold with mammalian cells which grow along the polymeric mold to produce the extracellular matrix of collagen or of other structural proteins. Once completed, the cells are removed, leaving behind the extracellular matrix.
  • the decellularized tissue (or polymer with attached extracellular matrix, in alternative embodiments) is treated with a solution in order to reduce the retained water in the tissue.
  • the treatment solution includes one or more polyols, other than glycerol. As shown below, embodiments treated with solutions described herein are less swollen and rigid than those treated with glycerol alone.
  • the one or more polyols can include at least one of 1 ,2 propanediol, 1 ,2 octanediol, 1 ,4 butanediol, fructose, xylitol, mannitol, sorbitol, lactulose, lactic acid, maltose, glucose, galactose, erythritol, lactobionic acid or its salts, and hyaluronic acid of various molecular weights and crosslinked to various degrees or not crosslinked.
  • the one or more other polyols are selected from the group consisting of 1 ,2 propanediol, 1 ,4 butanediol, and lactobionic acid, or combinations thereof.
  • the treatment solution may consist of about 50 volume percent (vol. %) 1 ,2 propanediol and about 50 vol. % 1 ,4 butanediol; or the treatment solution may consist of 1 ,2 propanediol and lactobionate at saturation in the solution.
  • the one or more polyols consists essentially of 1 ,2 propanediol.
  • the treatment solution may further include glycerol.
  • glycerol is present in the treatment solution at a concentration ranging from about 1 volume percent (vol. %) to about 50 vol. %, and the one or more other polyols are present at a concentration of about 50 vol. % to about 99 vol. %.
  • the treatment solution consists of 90 vol. % 1 ,2 propanediol and about 10 vol. % glycerol.
  • the treatment solution consists of 85 vol. % 1 ,4 butanediol and about 15 vol. % glycerol.
  • the glycerol is present in the solution at a concentration from about 20 vol. % to about 50 vol. %, and the one or more polyols are present at a concentration from about 50 vol. % to about 80 vol. %.
  • the treatment solution consists of about 50 vol. % 1 ,2 propanediol and about 50 vol. % glycerol.
  • the treatment solution may further include water.
  • water is present in the treatment solution at concentration of about 1 vol. % to about 20 vol. %.
  • the treatment solution can include glycerol ranging from about 15 vol. % to about 35 vol. %, one or more other polyols ranging from about 65 vol. % to about 85 vol. %, and the balance water.
  • the treatment solution includes about 10 vol. % water, about 30 vol. % glycerol, about 60 vol. % 1 ,2 propanediol, and lactobionate at saturation in the solution.
  • the treatment solution may include ethanol.
  • ethanol is present in the treatment solution at concentration of about 1 vol. % to about 20 vol. %.
  • the treatment solution can include glycerol ranging from about 15 vol. % to about 35 vol. %, one or more other polyols ranging from about 65 vol. % to about 85 vol. %, and the balance ethanol.
  • the treatment solution includes about 10 vol. % ethanol, about 30 vol. % glycerol, about 60 vol. % 1 ,2 propanediol, and lactobionate at saturation in the solution.
  • the decellularized tissue (or polymer with attached extracellular matrix, in alternative embodiments) is soaked in the treatment solution as described below. Excess treatment solution can be mechanically removed from the tissue, which helps remove the major part of the retained water.
  • the tissue is stored dry and used for fabrication or manufacturing of a bioprosthesis, for example, a heart valve. The foregoing process can be applied, for example, to decellularized pericardium of a mammalian donor for use in heart valve manufacturing. The valve may then be sterilized using ethylene oxide gas, ionizing radiation, and/or ultraviolet (UV) light.
  • UV ultraviolet
  • Sterilization with ethylene oxide gas, ionizing radiation, or UV light does not impair remodeling because neither method induces tissue fixation. Also, these sterilization methods are more robust and less complex from an industrial perspective than traditional aldehyde based sterilization processes, that involve set up and maintenance of controlled environments, with critical operating procedures.
  • the treatment solution can be applied to a bioprosthesis, for example a heart valve made of fresh decellularized tissue or of tissue produced via tissue engineering.
  • a bioprosthesis for example a heart valve made of fresh decellularized tissue or of tissue produced via tissue engineering.
  • the valve is soaked in the treatment solution one or more times for several hours, as described below. When removed from the treatment solution, a small amount of the treatment solution remaining in the valve is easily removed.
  • Some polyols such as 1 ,2 propanediol and 1 ,4 butanediol, are less viscous than glycerol, which helps in removing them from the valve.
  • the valve may be sterilized using ethylene oxide, ionizing radiation, and/or UV light and then stored dry until use.
  • the treatment with the solution includes immersing the tissue in the treatment solution at a temperature ranging from about 5°C to about 35°C for a time ranging from about 2 hours to about 100 hours.
  • treatment with the solution includes repeated immersions two to three times, each immersion time ranging from about 1 hour to about 20 hours.
  • the treatment with the solution may include spreading the treatment solution on the tissue or spraying it on the tissue.
  • the tissue and the treatment solution can be held under pressure greater than about 100 kPa to enhance movement of the treatment solution into the tissue.
  • the pressure under which the tissue and the treatment solution are held during the treatment can range from about 200 kPa to about 10,000 kPa.
  • the pressure under which the tissue and the treatment solution are held during the treatment can range from about 300 kPa to about 1 ,000 kPa.
  • the excess treatment solution can be removed mechanically from the treated tissue by, for example, contact with an absorbent fabric.
  • the treatment solution includes water
  • the treatment solution may remain, for example, within interstitial spaces of the extracellular matrix.
  • the treated tissue may be completely dried by exposing it to air for a time ranging from about 2 hours to about 96 hours at a temperature ranging from about 20°C to about 45°C.
  • the treated tissue of the implantable material may be dried to remove substantially all of the water, so that the implantable material is substantially free of water.
  • the treatment solution of one or more polyols and, optionally, glycerol remains within the interstitial spaces of the extracellular matrix, and preserves the integrity and flexibility of the implantable material without the need of storing it in a water based storage solution.
  • the dried tissue can be sterilized.
  • sterilizing the dried tissue may include exposing the dried tissue to ethylene oxide gas, avoiding temperatures above 50°C in order not to damage the tissue itself.
  • sterilizing the dried tissue may include exposing the dried tissue to ionizing radiation, such as gamma radiation.
  • sterilizing the dried tissue may include exposing the dried tissue to UV light.
  • the dried tissue may be sterilized by exposure to any combination of ethylene oxide gas, ionizing radiation, and UV light. As noted above, none of these sterilization methods induces tissue fixation, so remodeling is not impaired.
  • tissue is preserved in a stable, pliable state and may be stored for an extended period of time.
  • the methods described herein provide an alternative to aldehydes for sterilization and storage of fixed tissue, and increase the shelf life of non-fixed tissue.
  • Non-fixed tissue not treated according to the methods provided herein must be used within a few days or weeks from production or it quickly degenerates.
  • tissue/devices of the present disclosure can be sterilized in its final packaging and then stored at room temperature.
  • the preserved implantable material may be made ready for implanting by immersing the implantable material in a physiologic saline solution.
  • the preserved implantable material may be implanted as is and the host's blood and body fluids relied upon to rehydrate the material.
  • pericardium tissue was decellularized by immersion in a solution of 0.5% deoxycholate and 0.5% sodium dodecyl sulfate for 24 hours at 22°C with continuous shaking. Then the tissue was washed with phosphate buffered saline solution (PBS) for 24 hours (10 solution changes) at 22°C with continuous shaking (ref.: Cebotari, S. et al., Detergent Decellularization of Heart Valves for Tissue Engineering: Toxicological Effects of Residual Detergents on Human Endothelial Cells, Artificial Organs, 34: 206-210 (2010)). Other decellularization methods or tissue engineering techniques can be used.
  • PBS phosphate buffered saline solution
  • tissue sample 10 was immersed in pure glycerol for 16 hours at room temperature.
  • tissue sample 20 was immersed in pure 1 ,2 propanediol for 16 hours at room temperature.
  • tissue sample 30 was immersed in a solution of about 50 vol. % 1 ,2 propanediol and about 50 vol. % glycerol for 16 hours at room temperature.
  • each of the three tissue samples 10, 20, and 30 were blotted on adsorbent fabric and put as a sandwich between two sheets of adsorbent polymeric fabric and gently squeezed under a press to mechanically remove excess liquid. Then the three tissue samples were dried at room temperature for 24 hours, sealed in Tyvek® pouches, and sterilized by exposure to ethylene oxide gas.
  • FIGS. 1 -3 The three tissue samples after sterilization are shown in FIGS. 1 -3 for treatments A, B, and C, respectively.
  • the tissue sample 10 that received treatment A was observed to be more swollen and rigid with respect to the other two samples, but was still pliable.
  • the tissue sample 20 that received treatment B and the tissue sample 30 that received treatment C were perfectly pliable, soft and elastic. All the three tissue samples 10, 20, and 30 preserved their initial dimension and were soft enough to sew into a heart valve bioprosthesis. When put in physiologic saline solution they were observed to immediately recover their initial appearance.
  • decellularized bovine pericardium tissue was obtained as described above in Example 1 . This tissue was then used to prepare a stented valve 40.
  • valve 40 was then immersed in a solution of about 70 vol. % 1 ,2 propanediol and about 30 vol. % glycerol for 16 hours at room temperature. During immersion the valve leaflets were kept in the correct shape using soft polymer clips.
  • valve 40 after sterilization is shown in FIG. 4. After sterilization, the valve 40 was observed to be perfectly pliable and in a good shape.
  • patches of freshly harvested bovine pericardium tissue was washed several times in saline solution and selected to obtain suitable tissue for sewing tissue heart valves. The patches were then submitted to an initial treatment with a glutaraldehyde solution at low concentration 0.1 - 0.3% w/v for few hours at room temperature to fix the tissue.
  • tissue patches, a tissue patch 50, at tissue patch 60, a tissue patch 70, and a tissue patch 80 were submitted to different treatments A, B, C, and D, respectively.
  • treatment A the tissue patch 50 was immersed in pure glycerol for 16 hours at room temperature.
  • treatment B the tissue patch 60 was immersed in pure 1 ,2 propanediol for 16 hours at room temperature.
  • treatment C the tissue patch 70 was immersed in a solution of about 50 vol. % 1 ,2 propanediol and about 50 vol. % glycerol for 16 hours at room temperature.
  • treatment D the tissue patch 80 was immersed in a solution of about 85 vol. % 1 ,4 butanediol and about 15 vol. % glycerol for 16 hours at room temperature.
  • the four tissue patches 50, 60, 70 and 80 were blotted on adsorbent fabric and put as a sandwich between two sheets of adsorbent polymeric fabric and gently squeezed under a press to mechanically remove excess liquid. Then the three tissue patches were dried at room temperature for 24 hours, sealed in Tyvek® pouches, and sterilized by exposure to ethylene oxide gas.
  • FIGS. 5-8 The four tissue patches 50, 60, 70, and 80 after sterilization are shown in FIGS. 5-8 for treatments A, B, C, and D, respectively.
  • the tissue patches 50, 60, 70, and 80 were all observed to be soft and pliable.
  • patches of freshly harvested bovine pericardium tissue was washed several times in saline solution and selected to obtain suitable tissue for sewing tissue heart valves.
  • the patches were then submitted to an initial treatment with a glutaraldehyde solution at low concentration 0.1 - 0.3% w/v for few hours at room temperature to fix the tissue. These patches were then used for heart valve sewing.
  • valve 90 Three different heart valves, a valve 90, a valve 100, and a valve 1 10, made from the patches were submitted to different treatments A, B, and C, respectively.
  • treatment A the valve 90 was immersed in pure glycerol for 16 hours at room temperature.
  • treatment B the valve 100 was immersed in pure 1 ,2 propanediol for 16 hours at room temperature.
  • treatment C the valve 1 10 was immersed in a solution of about 50 vol. % 1 ,2 propanediol and about 50 vol. % glycerol for 16 hours at room temperature.
  • the valve leaflets were kept in the correct shape using soft polymer clips.
  • FIGS. 9A-1 1 B are photographs showing opposite sides of the valve 90 that received Treatment A.
  • FIGS. 10A and 10B are photographs showing opposite sides of the valve 100 that received Treatment B.
  • FIGS. 1 1A and 1 1 B are photographs showing opposite sides of the valve 1 10 that received Treatment C.
  • the valves 90, 100, and 1 10 were observed to be perfectly pliable and in a good shape.

Abstract

Un matériau implantable comprend un tissu de mammifère stérilisé décellularisé ayant une matrice extracellulaire, une pluralité d'espaces interstitiels de la matrice extracellulaire comprenant une solution d'un ou plusieurs polyols autres que le glycérol et, facultativement, du glycérol.
PCT/IB2017/051504 2017-03-15 2017-03-15 Matériau implantable et procédé de conservation WO2018167536A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2017/051504 WO2018167536A1 (fr) 2017-03-15 2017-03-15 Matériau implantable et procédé de conservation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2017/051504 WO2018167536A1 (fr) 2017-03-15 2017-03-15 Matériau implantable et procédé de conservation

Publications (1)

Publication Number Publication Date
WO2018167536A1 true WO2018167536A1 (fr) 2018-09-20

Family

ID=58398226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/051504 WO2018167536A1 (fr) 2017-03-15 2017-03-15 Matériau implantable et procédé de conservation

Country Status (1)

Country Link
WO (1) WO2018167536A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702378B2 (en) 2017-04-18 2020-07-07 Twelve, Inc. Prosthetic heart valve device and associated systems and methods
US10702380B2 (en) 2011-10-19 2020-07-07 Twelve, Inc. Devices, systems and methods for heart valve replacement
US10709591B2 (en) 2017-06-06 2020-07-14 Twelve, Inc. Crimping device and method for loading stents and prosthetic heart valves
US10729541B2 (en) 2017-07-06 2020-08-04 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US10751173B2 (en) 2011-06-21 2020-08-25 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
WO2020183222A1 (fr) * 2019-03-11 2020-09-17 Sorin Group Italia S.R.L. Procédé de fourniture de caractéristiques sur un matériau implantable mettant en jeu l'utilisation du laser, prothèses cardiovasculaires implantables et matériaux implantables traités selon ledit procédé
US10786352B2 (en) 2017-07-06 2020-09-29 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US10945835B2 (en) 2011-10-19 2021-03-16 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US11197758B2 (en) 2011-10-19 2021-12-14 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US11202704B2 (en) 2011-10-19 2021-12-21 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US11452599B2 (en) 2019-05-02 2022-09-27 Twelve, Inc. Fluid diversion devices for hydraulic delivery systems and associated methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058082A2 (fr) * 1998-05-14 1999-11-18 The Cleveland Clinic Foundation Traitement de tissus animaux implantables pour l'entreposage a sec
WO2001041828A1 (fr) * 1999-12-13 2001-06-14 Sulzer Carbomedics Inc. Traitements anti-calcification pour biomatières fixes
US20060073592A1 (en) * 2004-10-06 2006-04-06 Wendell Sun Methods of storing tissue matrices
US20080102439A1 (en) * 2006-10-27 2008-05-01 Bin Tian Biological tissue for surgical implantation
US20100030340A1 (en) * 1998-06-30 2010-02-04 Wolfinbarger Jr Lloyd Plasticized Grafts and Methods of Making and Using Same
EP2394673A1 (fr) * 2010-06-09 2011-12-14 Sorin Biomedica Cardio S.r.l. Procédé de préparation de tissu biologique pour prothèses biologiques

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058082A2 (fr) * 1998-05-14 1999-11-18 The Cleveland Clinic Foundation Traitement de tissus animaux implantables pour l'entreposage a sec
US20100030340A1 (en) * 1998-06-30 2010-02-04 Wolfinbarger Jr Lloyd Plasticized Grafts and Methods of Making and Using Same
WO2001041828A1 (fr) * 1999-12-13 2001-06-14 Sulzer Carbomedics Inc. Traitements anti-calcification pour biomatières fixes
US20060073592A1 (en) * 2004-10-06 2006-04-06 Wendell Sun Methods of storing tissue matrices
US20080102439A1 (en) * 2006-10-27 2008-05-01 Bin Tian Biological tissue for surgical implantation
EP2394673A1 (fr) * 2010-06-09 2011-12-14 Sorin Biomedica Cardio S.r.l. Procédé de préparation de tissu biologique pour prothèses biologiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CEBOTARI, S. ET AL.: "Detergent Decellularization of Heart Valves for Tissue Engineering: Toxicological Effects of Residual Detergents on Human Endothelial Cells", ARTIFICIAL ORGANS, vol. 34, 2010, pages 206 - 210

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10751173B2 (en) 2011-06-21 2020-08-25 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US11712334B2 (en) 2011-06-21 2023-08-01 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US11523900B2 (en) 2011-06-21 2022-12-13 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US11197758B2 (en) 2011-10-19 2021-12-14 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US11617648B2 (en) 2011-10-19 2023-04-04 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US10702380B2 (en) 2011-10-19 2020-07-07 Twelve, Inc. Devices, systems and methods for heart valve replacement
US10945835B2 (en) 2011-10-19 2021-03-16 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US11826249B2 (en) 2011-10-19 2023-11-28 Twelve, Inc. Devices, systems and methods for heart valve replacement
US11202704B2 (en) 2011-10-19 2021-12-21 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US11628063B2 (en) 2011-10-19 2023-04-18 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US11497603B2 (en) 2011-10-19 2022-11-15 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US10702378B2 (en) 2017-04-18 2020-07-07 Twelve, Inc. Prosthetic heart valve device and associated systems and methods
US11654021B2 (en) 2017-04-18 2023-05-23 Twelve, Inc. Prosthetic heart valve device and associated systems and methods
US10709591B2 (en) 2017-06-06 2020-07-14 Twelve, Inc. Crimping device and method for loading stents and prosthetic heart valves
US11464659B2 (en) 2017-06-06 2022-10-11 Twelve, Inc. Crimping device for loading stents and prosthetic heart valves
US10729541B2 (en) 2017-07-06 2020-08-04 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US11877926B2 (en) 2017-07-06 2024-01-23 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US10786352B2 (en) 2017-07-06 2020-09-29 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
WO2020183222A1 (fr) * 2019-03-11 2020-09-17 Sorin Group Italia S.R.L. Procédé de fourniture de caractéristiques sur un matériau implantable mettant en jeu l'utilisation du laser, prothèses cardiovasculaires implantables et matériaux implantables traités selon ledit procédé
US11452599B2 (en) 2019-05-02 2022-09-27 Twelve, Inc. Fluid diversion devices for hydraulic delivery systems and associated methods

Similar Documents

Publication Publication Date Title
WO2018167536A1 (fr) Matériau implantable et procédé de conservation
US10390946B2 (en) Method for the preparation of biological tissue for dry use in an implant
CA2666485C (fr) Tissu biologique pour implantation chirurgicale
JP3797673B2 (ja) 石灰化を軽減するための移植可能な生物学的組織の処理方法およびこのような方法で処理された生体補綴物
EP2640431B1 (fr) Processus de double réticulation devant favoriser la durabilité post-implantation de tissus bio-prosthétiques
JP4555570B2 (ja) 移植後の石灰化を軽減する生物補綴組織の処理
JP2008534067A (ja) 移植後石灰化を緩和する生体補綴組織の処理
US20110300625A1 (en) Tissue for prosthetic implants and grafts, and methods associated therewith
JP2004502499A (ja) 動物の角膜組織を含むバイオマテリアル
US20220072202A1 (en) Method for preparing biological tissue for surgical implantation
AU2021407693A1 (en) Biological prosthetic tissue processing method, and biological prosthetic heart valve
DK1978978T3 (en) Biocompatible tissue graft for implantation as well as the process for its preparation
WO2020038293A1 (fr) Procédé de traitement d'une valve biologique à l'aide d'une combinaison de réticulation enzymatique et de polyphénol de thé
RU2809478C2 (ru) Способ предотвращения разложения и дегенерации ткани, используемой в биопротезах
US9555162B2 (en) Phospholipid reduction in biological tissue

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17712846

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17712846

Country of ref document: EP

Kind code of ref document: A1